Curatis Holding AG (CURN)

Currency in CHF
25.0000
+0.5000(+2.04%)
Closed·
Unusual trading volume
CURN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
24.500025.0000
52 wk Range
9.720027.9000
Key Statistics
Bid/Ask
23.40 / 25.20
Prev. Close
24.5
Open
24.5
Day's Range
24.5-25
52 wk Range
9.72-27.9
Volume
14.85K
Average Volume (3m)
3.58K
1-Year Change
137.8641%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CURN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Curatis Holding AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington’s disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.

Employees
9

Compare CURN to Peers and Sector

Metrics to compare
CURN
Peers
Sector
Relationship
P/E Ratio
−92.9x−1.2x−0.5x
PEG Ratio
−1.120.050.00
Price/Book
2.9x2.1x2.6x
Price / LTM Sales
12.2x4.2x3.2x
Upside (Analyst Target)
292.4%19.7%47.4%
Fair Value Upside
Unlock16.6%7.7%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 24, 2026
EPS / Forecast
-0.05 / --
Revenue / Forecast
5.56M / --
EPS Revisions
Last 90 days

CURN Income Statement

People Also Watch

479.80
LONN
-3.87%
144.65
SIKA
-1.93%
22.040
KURN
-1.96%
67.90
BANB
+0.37%
136.40
CICN
+2.40%

FAQ

What Is the Curatis Holding (CURN) Stock Price Today?

The Curatis Holding stock price today is 25.0000 CHF.

What Stock Exchange Does Curatis Holding Trade On?

Curatis Holding is listed and trades on the Switzerland Stock Exchange.

What Is the Stock Symbol for Curatis Holding?

The stock symbol for Curatis Holding is "CURN."

What Is the Curatis Holding Market Cap?

As of today, Curatis Holding market cap is 128.8500M CHF.

What Is Curatis Holding's Earnings Per Share (TTM)?

The Curatis Holding EPS (TTM) is -0.2839.

From a Technical Analysis Perspective, Is CURN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Curatis Holding Stock Split?

Curatis Holding has split 1 times.

How Many Employees Does Curatis Holding Have?

Curatis Holding has 9 employees.

What is the current trading status of Curatis Holding (CURN)?

As of Apr 25, 2026, Curatis Holding (CURN) is trading at a price of 25.0000 CHF, with a previous close of 24.5000 CHF. The stock has fluctuated within a day range of 24.5000 CHF to 25.0000 CHF, while its 52-week range spans from 9.7200 CHF to 27.9000 CHF.

What Is Curatis Holding (CURN) Price Target According to Analysts?

The average 12-month price target for Curatis Holding is 98.1000 CHF, with a high estimate of 98.1 CHF and a low estimate of 98.1 CHF. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +292.40% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.